Oropharynx HPV-Independent

Primary Site Histology Schema Discriminator 1 Schema Discriminator 2 Year of Diagnosis
C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541 <Any value> 1, 9 <Any value>
C111 8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541 2 1, 9 2018-2024
C101 8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541 <Any value> 1, 9 2026-9998, 9999, <BLANK>

Notes

**See table above for primary sites and histologies for this schema** C019: Base of tongue, NOS C024: Lingual tonsil C051: Soft palate, NOS C052: Uvula C090: Tonsillar fossa C091: Tonsillar pillar C098: Overlapping lesion of tonsil C099: Tonsil, NOS C100: Vallecula C101: Anterior surface of epiglottis C102: Lateral wall of oropharynx C103: Posterior wall of oropharynx C104: Branchial cleft (site of neoplasm) C108: Overlapping lesion of oropharynx C109: Oropharynx, NOS C111: Pharyngeal tonsil **Note 1:** **Sources used in the development of this schema** * SEER Extent of Disease 1988: Codes and Coding Instructions (3rd Edition, 1998) (https://seer.cancer.gov/archive/manuals/EOD10Dig.3rd.pdf) * SEER Summary Staging Manual-2000: Codes and Coding Instructions (https://seer.cancer.gov/tools/ssm/ssm2000/) * Collaborative Stage Data Collection System, version 02.05: https://cancerstaging.org/cstage/Pages/default.aspx * Chapter 11 *Oropharynx (p16-) and Hypopharynx*, in the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Used with permission of the American College of Surgeons, Chicago, Illinois. **Note 2:** **Other EOD Schemas with Oropharynx sites** * **GIST**: 8935-8936 * **Kaposi Sarcoma**: 9140 * **Melanoma Head and Neck**: 8720-8790 * **Mycosis Fungoides**: 9700-9701 * **Oropharynx HPV-Mediated (2018-2025)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541) * **Oropharynx HPV-Associated (p16+) (2026+)**: C019, C024, C051-C052, C090-C091, C098-C099, C100, C102-C104, C108-C109 and Schema Discriminator 2: Oropharyngeal p16: 2 (8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541) * **Nasopharynx (2018-2024)** C111 AND Schema Discriminator 1: Nasopharynx/PharyngealTonsil:1 (8000-8700, 8940-8960, 8965-8983, 9000, 9050-9111, 9270, 9300-9312, 9340-9363, 9380-9539, 9541) or Year of Diagnosis is 2025 or later * **Soft Tissue Head and Neck**: 8710-8714, 8800-8803, 8810-8905, 8912, 8921, 8932-8934, 8963-8964, 8990, 8992, 9010-9016, 9030-9043, 9045, 9121-9138, 9141-9230, 9240-9262, 9271-9290, 9320-9330, 9364-9373, 9540, 9542-9580, 9582 * **Soft Tissue Rare**: 8804-8806, 8910, 8920, 8930-8931, 8991, 9020, 9044, 9120, 9231, 9581 **Note 3:** **p16 immunotesting** * p16 immunotesting is mandatory to use this staging system for HPV-associated cancer. HPV by in situ hybridization (ISH) may be done as an alternative. * If a case of oropharyngeal cancer has p16+, then the Oropharynx HPV-Associated schema is used. * If case is p16- or does not have p16, then this schema is used.

Data Items

Name Default Value Used in Derivation NAACCR Item Required By Metadata
Year of Diagnosis Yes NAACCR #390
dateOfDiagnosis 		None
Primary Site Yes NAACCR #400
primarySite 		None
Histology Yes NAACCR #522
histologicTypeIcdO3 		None
Behavior No NAACCR #523
behaviorCodeIcdO3 		None
Schema Discriminator 1 Yes NAACCR #3926
schemaDiscriminator1 		All SSDI
Schema Discriminator 2 9 Yes NAACCR #3927
schemaDiscriminator2 		All SSDI
Type of Reporting Source No NAACCR #500
typeOfReportingSource 		None
Tumor Size Clinical No NAACCR #752
tumorSizeClinical 		None
Tumor Size Pathological No NAACCR #754
tumorSizePathologic 		None
Tumor Size Summary 999 No NAACCR #756
tumorSizeSummary 		None
Regional Nodes Positive 99 No NAACCR #820
regionalNodesPositive 		None
Regional Nodes Examined 99 No NAACCR #830
regionalNodesExamined 		None
EOD Primary Tumor 999 Yes NAACCR #772
eodPrimaryTumor 		None
EOD Regional Nodes 999 Yes NAACCR #774
eodRegionalNodes 		None
EOD Mets 00 Yes NAACCR #776
eodMets 		None
SS2018 No NAACCR #764
summaryStage2018 		None
Grade Clinical 9 Yes NAACCR #3843
gradeClinical 		All SSDI
Grade Pathological 9 Yes NAACCR #3844
gradePathological 		All SSDI
Grade Post Therapy Clin (yc) No NAACCR #1068
gradePostTherapyClin 		COC
NPCR
SEER		 SSDI
Grade Post Therapy Path (yp) No NAACCR #3845
gradePostTherapy 		CCCR/Canada
COC
NPCR
SEER		 SSDI
Extranodal Exten H&N Clin 8 No NAACCR #3831
extranodalExtensionHeadNeckClin 		COC
SEER (RC)		 SSDI
Extranodal Exten H&N Path X.8 No NAACCR #3832
extranodalExtensionHeadNeckPath 		CCCR/Canada
COC
SEER 2018–2023
SEER (RC) 2024–		 SSDI
LN Size XX.8 No NAACCR #3883
lnSize 		CCCR/Canada
COC
SEER 2018–2023
SEER (RC) 2024–		 SSDI
SEER_SSF1: SEER Site-Specific Fact 1 99 No NAACCR #3700
seerSiteSpecificFact1 		None
Neoadjuvant Therapy 9 No NAACCR #1632
neoadjuvantTherapy 		SEER 2021– SSDI 2021–
Neoadjuvant Therapy – Clinical Response 99 No NAACCR #1633
neoadjuvTherapyClinicalResponse 		SEER 2021– SSDI 2021–
Neoadjuvant Therapy – Treatment Effect 9 No NAACCR #1634
neoadjuvTherapyTreatmentEffect 		SEER 2021– SSDI 2021–

Initial Context

Staging Methods

Expand All | Collapse All

Summary Stage 2018

Start

  2. Derived Summary Grade
  3. derived_summary_grade

Next Step

  2. EOD Primary Tumor
  3. ss2018_t

Next Step

  2. EOD Regional Nodes
  3. ss2018_n

Next Step

  2. EOD Mets
  3. ss2018_m

Next Step

  2. Summary Stage
  3. ss2018_derived

End

Outputs

Name Default Value Description NAACCR Item Metadata
Schema ID 00111 NAACCR #3800
schemaId 		None
Derived Version {{ctx_alg_version}} None None
Derived Summary Stage 2018 9 NAACCR #762
derivedSummaryStage2018 		None
Derived Summary Grade 2018 <BLANK> NAACCR #1975
derivedSummaryGrade2018 		None